Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 1 Dec 2006

Utecht Kyle N, Hiles Jon J, Kolesar Jill

Abstract excerpt

PURPOSE: The effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors were examined. SUMMARY: The bioavailability and metabolism of cyclosporine and tacrolimus are primarily controlled by efflux pumps and members of the cytochrome P-450 (CYP) isoenzyme system found in the liver and gastrointestinal tract. The number and severity of adverse effects from these drugs are related to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Calcineurin Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclosporine

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Tacrolimus

Source

Identifiers

PMID: 17106006
DOI: 10.2146/ajhp060080

Genes

PGP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.PMID 17106006Read ↗

Pharmacogenetics of calcineurin inhibitors in renal transplantation.Semantic proximity Read ↗

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentSemantic proximity Read ↗

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.Semantic proximity Read ↗

The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?Semantic proximity Read ↗

Genetic polymorphisms and individualized tacrolimus dosing.Semantic proximity Read ↗

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.Semantic proximity Read ↗

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantationSemantic proximity Read ↗

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.Semantic proximity Read ↗

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Semantic proximity Read ↗

Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.